Bristol-Myers Squibb shares decline for the seventh straight session, down 5% over the past month despite a 4% year-to-date gain.
Bristol-Myers Squibb (BMY) shares fell 0.9% to $55.64 on Monday, marking the seventh consecutive session of declines. The stock has dropped 3.5% over the prior six sessions and is down 5% over the past month.
The pharma giant’s shares have advanced 4% year-to-date, underperforming broader sector trends. The recent downturn follows a period of volatility amid shifting investor sentiment in the healthcare sector.
No immediate market reaction was reported, though the extended losing streak reflects ongoing pressure on the stock.